Research ArticleTUMOR MICROENVIRONMENT

Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity

See allHide authors and affiliations

Science Immunology  21 Jun 2019:
Vol. 4, Issue 36, eaaw2004
DOI: 10.1126/sciimmunol.aaw2004

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Using cell death to resurrect antitumor immunity

Dying cells can trigger activation of the immune system. Here, Snyder et al. have engineered cells that can be induced to undergo necroptotic cell death. By injecting these cells directly into tumors, they have examined the ability of these dying cells to promote antitumor responses in situ and at a distant site harboring syngeneic tumor. In addition to promoting immune response in situ, these injected cells drove a systemic immune response driven by conventional dendritic cells 1 (cDC1s) and CD8+ T cells that promoted regression of tumor at the distant site as well. Most impressively, they found that the dying cells did not have to express tumor-specific antigens to promote antitumor immunity.

View Full Text